Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

'Cell-in-cell' mechanism explains how blood cancer uses bone marrow to evade treatment

2.

Coupling dye and fiducial marking can improve precision in pulmonary nodule surgical resection

3.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

4.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

5.

Gedatolisib Combo Approved for Advanced Breast Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot